Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, In Worse Shape Than Previously Thought, Gets More Cash From Solexa

NEW YORK, Oct. 29 (GenomeWeb News) - Solexa will pour additional cash into Lynx Therapeutics in an attempt to speed the development of new sequencing technologies in time for their merger, the firms said today.

 

For the Lynx, the merger--and especially the additional cash infusion--appears to be its only lifeline: The floundering gene expression-analysis company today said that its independent auditor, Ernst & Young, recently raised "substantial doubts" about its ability to stay solvent. Lynx said it reported this announcement to the US Securities and Exchange Commission in an amended filing to its 2003 year-end earning report.

 

In a paragraph attached to the amended report, Lynx said the company's "losses since inception, including a net loss for the six months ended June 30 ... [indicates that the company] "will require additional funding to continue its business activities through at least December 31, 2005 and raises substantial doubt as to Lynx' ability to continue as a going concern."

 

Lynx has pocketed at least $2.5 million from Solexa as part of the companies' merger agreement, disclosed in August. Today's announced means Solexa will give Lynx an additional undisclosed sum to help it "accelerate development of ... [a new] DNA sequencing instrument.

 

"The intent of this [new funding] is to accelerate the integration of both companies' technologies prior to completing" the merger, the firms said in a statement.

 

As GenomeWeb News reported in September, Lynx and Solexa signed a definitive merger agreement. As part of the merger, which is expected to be completed later this year, Lynx will issue up to 29.5 million shares in exchange for all of the outstanding shares and share options of Solexa. The combined company will continue to operate both in the USand in the UKand will trade on the Nasdaq SmallCap Market under the tickers symbol LYNX.

 

Under a separate agreement, Lynx has received $1.25 million in loan advances from Solexa. It will receive another $500,000 following the merger agreement and $750,000 in October. The cash infusion announced today is in addition to this $2.5 million amount.

 

The mew company plans to develop novel DNA sequencing technology, based on molecular arrays, and to release its first commercial instrument for whole genome resequencing and for gene-expression analysis by sequencing next year.

 

Solexa's $14.4 million financing round was led by Amadeus Capital Partners. Existing investors Abingworth Management, Schroder Venture Life Sciences, and Oxford Bioscience Partners also participated. Including the Series B round, Solexa has raised $40 million in total.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.